BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

269 related articles for article (PubMed ID: 30868297)

  • 21. Molecular Profiling of Pheochromocytoma and Abdominal Paraganglioma Stratified by the PASS Algorithm Reveals Chromogranin B as Associated With Histologic Prediction of Malignant Behavior.
    Stenman A; Svahn F; Hojjat-Farsangi M; Zedenius J; Söderkvist P; Gimm O; Larsson C; Juhlin CC
    Am J Surg Pathol; 2019 Mar; 43(3):409-421. PubMed ID: 30451732
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Telomerase Activation and ATRX Mutations Are Independent Risk Factors for Metastatic Pheochromocytoma and Paraganglioma.
    Job S; Draskovic I; Burnichon N; Buffet A; Cros J; Lépine C; Venisse A; Robidel E; Verkarre V; Meatchi T; Sibony M; Amar L; Bertherat J; de Reyniès A; Londoño-Vallejo A; Favier J; Castro-Vega LJ; Gimenez-Roqueplo AP
    Clin Cancer Res; 2019 Jan; 25(2):760-770. PubMed ID: 30301828
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Metastatic risk factors in pheochromocytoma/paraganglioma].
    Rebrova DV; Loginova OI; Vorobyev SL; Vorokhobina NV; Kozorezova ES; Indeykin FA; Savelyeva TV; Sleptsov IV; Chernikov RA; Fedorov EA; Semenov AA; Chinchuk IK; Shikhmagomedov SS; Alekseev MA; Krasnov LM; Rusakov VF
    Probl Endokrinol (Mosk); 2023 Oct; 70(2):37-45. PubMed ID: 38796759
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Flow cytometric DNA analysis for determination of malignant potential in adrenal pheochromocytoma or paraganglioma: an Indian experience.
    Shah MJ; Karelia NH; Patel SM; Desai NS; Mehta HV; Singh S
    Ann Surg Oncol; 2003 May; 10(4):426-31. PubMed ID: 12734092
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pheochromocytoma of the Adrenal gland Scaled Score (PASS) to separate benign from malignant neoplasms: a clinicopathologic and immunophenotypic study of 100 cases.
    Thompson LD
    Am J Surg Pathol; 2002 May; 26(5):551-66. PubMed ID: 11979086
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Succinate Dehydrogenase Complex Iron Sulfur Subunit B (SDHB) Immunohistochemistry in Pheochromocytoma, Head and Neck Paraganglioma, Thoraco-Abdomino-Pelvic Paragangliomas: Is It a Good Idea to Use in Routine Work?
    Gul AE; Keser SH; Barisik NO; Gurbuz YS; Sensu S; Erdogan N
    Asian Pac J Cancer Prev; 2021 Jun; 22(6):1721-1729. PubMed ID: 34181326
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Correlation of the genotype of paragangliomas and pheochromocytomas with their metabolic phenotype on 3,4-dihydroxy-6-18F-fluoro-L-phenylalanin PET.
    Rischke HC; Benz MR; Wild D; Mix M; Dumont RA; Campbell D; Seufert J; Wiech T; Rössler J; Weber WA; Neumann HP
    J Nucl Med; 2012 Sep; 53(9):1352-8. PubMed ID: 22836345
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Histological grading of adrenal and extra-adrenal pheochromocytomas and relationship to prognosis: a clinicopathological analysis of 116 adrenal pheochromocytomas and 30 extra-adrenal sympathetic paragangliomas including 38 malignant tumors.
    Kimura N; Watanabe T; Noshiro T; Shizawa S; Miura Y
    Endocr Pathol; 2005; 16(1):23-32. PubMed ID: 16000843
    [TBL] [Abstract][Full Text] [Related]  

  • 29. MicroRNA 183 family profiles in pheochromocytomas are related to clinical parameters and SDHB expression.
    Pillai S; Lo CY; Liew V; Lalloz M; Smith RA; Gopalan V; Lam AK
    Hum Pathol; 2017 Jun; 64():91-97. PubMed ID: 28412207
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Overexpression of miR-210 is associated with SDH-related pheochromocytomas, paragangliomas, and gastrointestinal stromal tumours.
    Tsang VH; Dwight T; Benn DE; Meyer-Rochow GY; Gill AJ; Sywak M; Sidhu S; Veivers D; Sue CM; Robinson BG; Clifton-Bligh RJ; Parker NR
    Endocr Relat Cancer; 2014 Jun; 21(3):415-26. PubMed ID: 24623741
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Clinical presentation and penetrance of pheochromocytoma/paraganglioma syndromes.
    Benn DE; Gimenez-Roqueplo AP; Reilly JR; Bertherat J; Burgess J; Byth K; Croxson M; Dahia PL; Elston M; Gimm O; Henley D; Herman P; Murday V; Niccoli-Sire P; Pasieka JL; Rohmer V; Tucker K; Jeunemaitre X; Marsh DJ; Plouin PF; Robinson BG
    J Clin Endocrinol Metab; 2006 Mar; 91(3):827-36. PubMed ID: 16317055
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Epithelial to mesenchymal transition is activated in metastatic pheochromocytomas and paragangliomas caused by SDHB gene mutations.
    Loriot C; Burnichon N; Gadessaud N; Vescovo L; Amar L; Libé R; Bertherat J; Plouin PF; Jeunemaitre X; Gimenez-Roqueplo AP; Favier J
    J Clin Endocrinol Metab; 2012 Jun; 97(6):E954-62. PubMed ID: 22492777
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Composite Pheochromocytoma/Paraganglioma-Ganglioneuroma: A Clinicopathologic Study of Eight Cases with Analysis of Succinate Dehydrogenase.
    Gupta S; Zhang J; Erickson LA
    Endocr Pathol; 2017 Sep; 28(3):269-275. PubMed ID: 28752484
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Prediction of malignant behavior of pheochromocytomas and paragangliomas using immunohistochemical techniques.
    Kumaki N; Kajiwara H; Kameyama K; DeLellis RA; Asa SL; Osamura RY; Takami H
    Endocr Pathol; 2002; 13(2):149-56. PubMed ID: 12165664
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Role of positron emission tomography and bone scintigraphy in the evaluation of bone involvement in metastatic pheochromocytoma and paraganglioma: specific implications for succinate dehydrogenase enzyme subunit B gene mutations.
    Zelinka T; Timmers HJ; Kozupa A; Chen CC; Carrasquillo JA; Reynolds JC; Ling A; Eisenhofer G; Lazúrová I; Adams KT; Whatley MA; Widimsky J; Pacak K
    Endocr Relat Cancer; 2008 Mar; 15(1):311-23. PubMed ID: 18310297
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Emerging molecular markers of metastatic pheochromocytomas and paragangliomas.
    Goncalves J; Lussey-Lepoutre C; Favier J; Gimenez-Roqueplo AP; Castro-Vega LJ
    Ann Endocrinol (Paris); 2019 Jun; 80(3):159-162. PubMed ID: 31053249
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Metastatic sympathetic paraganglioma in a patient with loss of the SDHC gene.
    Rich T; Jackson M; Roman-Gonzalez A; Shah K; Cote GJ; Jimenez C
    Fam Cancer; 2015 Dec; 14(4):615-9. PubMed ID: 26162468
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Phaeochromocytomas and paragangliomas: A difference in disease behaviour and clinical outcomes.
    Ezzat Abdel-Aziz T; Prete F; Conway G; Gaze M; Bomanji J; Bouloux P; Khoo B; Caplin M; Mushtaq I; Smart J; Kurzawinski TR
    J Surg Oncol; 2015 Oct; 112(5):486-91. PubMed ID: 26337393
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Germline SDHB mutations are common in patients with apparently sporadic sympathetic paragangliomas.
    Klein RD; Jin L; Rumilla K; Young WF; Lloyd RV
    Diagn Mol Pathol; 2008 Jun; 17(2):94-100. PubMed ID: 18382370
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pheochromocytomas and Paragangliomas: An Update on Recent Molecular Genetic Advances and Criteria for Malignancy.
    Guo Z; Lloyd RV
    Adv Anat Pathol; 2015 Sep; 22(5):283-93. PubMed ID: 26262510
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.